1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice

Abstract

METex14 skipping is present in 3–4% of patients with aNSCLC. Several MET-specific targeted therapies have recently been licensed, however the lack of randomized studies make inferences on comparative effectiveness complex. We evaluated treatment patterns and progression-free survival (PFS) using real-world data collected prior to the regulatory approvals of MET-specific tyrosine kinase inhibitors (TKIs). Five real-world datasets of patients with METex14 skipping aNSCLC were pooled (data collected: 2011–2020); published data from a Western Canadian province, three international non-interventional studies, and French routine practice data. Patient records were included using a common data model with aligned definitions, and the best available definition of PFS was used. The analysis included 248 patients (54% female, 53% with smoking history), with a median age of 72 years. Of the 516 lines of therapy included, the majority could be categorized as chemotherapies (204), MET inhibitors (137; over 90% were crizotinib), or immunotherapy (119; mostly pembrolizumab and nivolumab). In general, patients received chemotherapy as a first-line therapy (118/220 identifiable lines). Across all treatment classes and treatment lines, median PFS (95% CI) were short; 5.0 (4.5, 7.5) vs 3.9 months (3.4, 5.2) for treatment-naïve vs previously treated patients receiving chemotherapy; 8.0 (4.0, 11.1) vs 7.0 months (5.6, 9.9) for MET inhibitors; and 3.6 (2.0, 10.2) vs 3.3 months (2.5, 5.7) for immunotherapies. This international real-world analysis – conducted prior to the approval of MET-specific TKI therapies – showed that outcomes for patients with METex14 skipping aNSCLC were poor across all available therapy classes and treatment lines.